SecBot SecBot
PRESS-RELEASE ·Filed Aug 10, 2026

PROK

ProKidney
NEUTRAL
Impact 5/10
Horizonmonths Processed3mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The completion of accelerated approval enrollment removes a key binary risk and sets a clear catalyst timeline (Q2 2027 topline data). However, the high cash burn and pre-revenue status mean the stock will trade on pipeline updates rather than financials. Monitor for full enrollment completion of PROACT 1 in H2 2026 and any partnering or financing announcements given the ~9-month cash runway buffer.

DirectionNeutral
Confidencehigh
Horizonmonths

REACT

● Neutral Named in this press release
Impact
Phase
Phase 3
Time to market
If Phase 3 PROACT 1 data is positive in Q2 2027 and an accelerated approval filing follows, a potential FDA decision could come in late 2027 or 2028. Commercial launch would follow approval.
Next catalyst
None dated

What to watchThe next major catalyst is the Phase 3 PROACT 1 topline data readout, expected in Q2 2027. Positive results could unlock an accelerated approval filing under FDA's RMAT pathway, while a miss would likely devastate the stock given the company is a single-asset developer. A softer near-term event is the KOL virtual event on October 27, 2026, which may provide updated mechanism-of-action data from ASN Kidney Week.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.61
T+0 close · Aug 10, 2026 · via day close
Latest settled
−30.43%
T+60 · $1.12
Vs SPY
−29.95%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 11 $1.61entry
  2. T+1 · 3mo ago −8.07%α −8.32% · $1.48
  3. T+5 · 3mo ago −14.29%α −13.88% · $1.38
  4. T+20 · 2mo ago +14.91%α +15.97% · $1.85
  5. T+60 · 13d ago −30.43%α −29.95% · $1.12
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

ProKidney reported Q2 2026 financial results with no revenue or EPS guidance to analyze, as the company is pre-commercial. The key highlight is completing enrollment of ~320 patients for the PROACT 1 accelerated approval efficacy analysis, with topline eGFR slope results expected in Q2 2027, a major derisking milestone. Cash burn continues, with $181.6 million in cash as of June 30, 2026, down from $224.9 million in Q1 2026, providing runway into mid-2027.

Key Financial Metrics

EPS
−$0.15
Revenue
$150.0K
-32.1% YoY
Rating
in line

Key Facts

  • Completed enrollment of ~320 patients for the PROACT 1 accelerated approval efficacy analysis
  • Topline eGFR slope results anticipated in Q2 2027
  • On track for full enrollment of ~470 patients in PROACT 1 in H2 2026
  • Cash, cash equivalents, and marketable securities: $181.6 million at June 30, 2026 (vs $224.9 million at March 31, 2026)
  • Net loss before noncontrolling interest: $46.4 million in Q2 2026 vs $37.0 million in Q2 2025
  • Net loss per share available to Class A common stockholders: $(0.15) in Q2 2026 vs $(0.13) in Q2 2025
  • R&D expenses increased to $36.1 million in Q2 2026 from $25.9 million in Q2 2025, driven by PROACT 1 study costs
  • Appointed Kenneth Locke as Chief Technical Officer in June 2026
  • 302,312,504 Class A and Class B common shares outstanding at June 30, 2026

Financial Impact

Cash burn rate of ~$43.3M per quarter (Q2 2026), with cash runway into mid-2027

cashnet lossR&D expensesoperating loss

Risk Factors

  • Clinical trial failure (eGFR slope may not meet statistical significance in Q2 2027)
  • Cash runway only into mid-2027, likely needs additional financing before data readout
  • High dilution: Class A shares outstanding increased from ~142M to ~206M since December 2025

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
67% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3342213

Track record

13 reports on PROK

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +13.51% at T+1 after the Oct 29, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 12, 20264d ago Press Release Bearish 7/10 Entry $1.05 to $1.04 Now $1.04 +0.48% ▲ +0.48% −1.43% vs SPY
  2. Nov 12, 20264d ago 424B5 Bearish 6/10 Entry $1.15 to $1.05 Now $1.04 +9.57% ▲ +9.13% +8.77% vs SPY
  3. Nov 12, 20265d ago EFFECT Bearish 5/10 Entry $1.15 to $1.05 Now $1.04 +9.57% ▲ +9.13% +8.77% vs SPY
  4. Nov 9, 20267d ago 8-K Neutral 3/10 Entry $1.15 to $1.11 Now $1.04 −9.57% ▼ −3.48% −3.11% vs SPY
  5. Oct 29, 202618d ago 8-K Bearish 6/10 Entry $1.30 to $1.12 Now $1.04 +19.69% ▲ +13.51% +13.03% vs SPY
  6. Oct 29, 202618d ago S-3 Bearish 6/10 Entry $1.30 to $1.12 Now $1.04 +19.69% ▲ +13.51% +13.03% vs SPY
  7. Oct 22, 202625d ago Press Release Neutral 3/10 Entry $1.43 to $1.41 Now $1.04 −27.27% ▼ −1.40% −0.88% vs SPY
  8. Aug 10, 202614w ago 8-K Neutral 5/10 No price data
  9. Aug 10, 202614w ago Press Release Neutral 5/10 Viewing Entry $1.61 to $1.48 Now $1.04 −35.40% ▼ −8.07% −8.32% vs SPY
  10. May 15, 202626w ago 8-K Neutral 4/10 No price data
Showing 10 of 13

US Market Status

Market Closed · Opens in 6h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 10, 2026